TheStreet lowered shares of Eli Lilly And Co (NYSE:LLY) from a b+ rating to a c+ rating in a research note released on Thursday morning, TheStreetRatingsTable reports.
Several other equities research analysts have also recently issued reports on the stock. Cantor Fitzgerald restated a buy rating on shares of Eli Lilly And Co in a report on Monday, February 4th. UBS Group dropped their target price on shares of Eli Lilly And Co from $107.53 to $100.00 and set an average rating on the stock in a report on Friday, February 8th. Bank of America set a $129.00 target price on shares of Eli Lilly And Co and gave the stock a hold rating in a report on Thursday, March 21st. Citigroup set a $124.00 target price on shares of Eli Lilly And Co and gave the stock a hold rating in a report on Tuesday, February 26th. Finally, JPMorgan Chase & Co. assumed coverage on shares of Eli Lilly And Co in a report on Tuesday, March 12th. They issued an overweight rating and a $140.00 target price on the stock. Ten analysts have rated the stock with a hold rating and twelve have assigned a buy rating to the company’s stock. Eli Lilly And Co presently has an average rating of Buy and an average target price of $118.83.
Shares of LLY stock opened at $116.22 on Thursday. Eli Lilly And Co has a 12-month low of $80.96 and a 12-month high of $132.13. The company has a debt-to-equity ratio of 5.50, a quick ratio of 0.85 and a current ratio of 1.12. The company has a market capitalization of $112.42 billion, a P/E ratio of 20.94, a P/E/G ratio of 2.05 and a beta of 0.27.
The firm also recently declared a quarterly dividend, which will be paid on Monday, June 10th. Stockholders of record on Friday, May 17th will be paid a dividend of $0.645 per share. This represents a $2.58 annualized dividend and a dividend yield of 2.22%. The ex-dividend date of this dividend is Thursday, May 16th. Eli Lilly And Co’s dividend payout ratio is presently 46.49%.
In other news, SVP Enrique A. Conterno sold 25,000 shares of the firm’s stock in a transaction on Friday, February 15th. The shares were sold at an average price of $121.00, for a total transaction of $3,025,000.00. The sale was disclosed in a filing with the SEC, which is available through this hyperlink. Also, insider Donald A. Zakrowski sold 1,000 shares of the firm’s stock in a transaction on Friday, March 1st. The shares were sold at an average price of $127.01, for a total transaction of $127,010.00. The disclosure for this sale can be found here. Insiders have sold a total of 870,959 shares of company stock worth $109,672,752 in the last quarter. Corporate insiders own 0.11% of the company’s stock.
Hedge funds have recently made changes to their positions in the company. Athena Capital Advisors LLC bought a new stake in shares of Eli Lilly And Co during the 4th quarter valued at $26,000. Wakefield Asset Management LLLP bought a new stake in Eli Lilly And Co in the 4th quarter valued at $27,000. Larson Financial Group LLC bought a new stake in Eli Lilly And Co in the 4th quarter valued at $29,000. Ironwood Financial llc bought a new stake in Eli Lilly And Co in the 4th quarter valued at $30,000. Finally, Trust Department MB Financial Bank N A increased its holdings in Eli Lilly And Co by 54.7% in the 1st quarter. Trust Department MB Financial Bank N A now owns 232 shares of the company’s stock valued at $30,000 after acquiring an additional 82 shares during the last quarter. Hedge funds and other institutional investors own 79.17% of the company’s stock.
Eli Lilly And Co Company Profile
Eli Lilly and Company discovers, develops, manufactures, and markets pharmaceutical products worldwide. The company operates in two segments, Human Pharmaceutical Products and Animal Health Products. It offers endocrinology products for the treatment of diabetes; osteoporosis in postmenopausal women and men; and human growth hormone deficiency and pediatric growth conditions.
Read More: What does relative strength index mean?
Receive News & Ratings for Eli Lilly And Co Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eli Lilly And Co and related companies with MarketBeat.com's FREE daily email newsletter.